Investors | Xemperia SA

Investors

Investing in the future of cancer early detection

Cancer is one of the world’s largest healthcare challenges. Breast cancer is the most diagnosed cancer in women worldwide, creating a major need for early detection.

XEMPERIA developed differentiated blood-based approaches to complement existing methods and make earlier cancer detection more effective to save more lives

XEMPERIA has protected the technologies covering both its immune-cell diagnostic approach and DNA-based nanosensors.

Business Model

Our business model is based on a strategic partnership with a global leader, as soon as the validation study is successfully completed.

XEMPERIA develops and protects the innovation. A global IVD partner provides the infrastructure to bring it to millions of women.

Value chain to global market

XEMPERIA: Technology + IP + clinical validation
GLOBAL IVD PARTNER: Regulatory + industrialization + distribution
SCREENING CENTERS & PHYSICIANS: Prescribe the test
MEDICAL LABORATORIES: Perform the PCR test
MILLIONS OF WOMEN: Will benefit from early breast cancer detection

Road map and investment opportunity

Why investing with XEMPERIA?

A differentiated biological approach

Rather than looking only for tumor-derived material we look for the body response to breast cancer.

A clear lead indication

Breast cancer is our first clinical and commercial focus, addressing a large unmet need in early detection.

A validated scientific foundation

Our technology originates from more than 25 years of translational cancer research and an initial clinical proof of concept.

Multiple future opportunities

The underlying technologies may be adapted to additional cancer types and diagnostic applications as development progresses.

Open investment opportunity

XEMPERIA is now looking for CHF 3 M to validate the very promising results of breast cancer detection blood test in a larger study, taking this product to enter the strategic partnership phase.

In case of interest, please contact: investors@xemperia.com or curzio.ruegg@xemperia.com

Investment disclaimer

Investing in a start-up involves significant risk, including the potential loss of the entire investment. Information on this website is provided for general information only and does not constitute investment advice or an offer to invest in XEMPERIA.